Menopause and Hormone Therapy

Menopause is the permanent cessation of menstruation that follows the loss of ovarian follicular activity, marked clinically by twelve consecutive months without a period. The surrounding transition can bring vasomotor symptoms (hot flushes and night sweats), genitourinary changes, and sleep and mood disturbances. Menopausal hormone therapy is the use of estrogen, with or without a progestogen, to relieve symptoms, and its benefit-risk balance has been redefined by large randomized evidence and successive position statements.

Definition

Menopause is the permanent end of menstruation due to loss of ovarian function, defined retrospectively after twelve months of amenorrhea; menopausal hormone therapy is the administration of estrogen (with a progestogen when the uterus is present) to manage menopausal symptoms.

Scope

The entry describes the biology of the menopause transition, the rationale for and principal considerations of hormone therapy, and how guidance has evolved. It is a reference and educational overview and gives no dosing, regimen, or individualized treatment advice; such decisions rest with current guidelines and clinical assessment.

Key concepts

• Ovarian follicular depletion
• Vasomotor symptoms
• Genitourinary syndrome of menopause
• Estrogen and progestogen therapy
• Benefit-risk balance and the timing hypothesis
• Shared decision-making

Mechanisms

Menopause results from depletion of ovarian follicles and the consequent fall in estrogen production, which underlies vasomotor and genitourinary symptoms and changes in bone and other estrogen-responsive tissues. Hormone therapy replaces estrogen to relieve these symptoms; a progestogen is added when the uterus is present to protect the endometrium. The Women's Health Initiative randomized trial reshaped understanding of the systemic risks and benefits of combined therapy, and later analyses emphasized that the balance varies with age and time since menopause (Writing Group for the Women's Health Initiative Investigators, 2002; Pinkerton, 2020).

Clinical relevance

Menopausal symptoms are common reasons for primary-care visits in midlife, and hormone therapy is one option whose appropriateness depends on symptom severity, age, time since menopause, and individual risk factors. This entry summarizes the concepts and evidence base for orientation; it does not recommend whether or how any individual should use hormone therapy, which is determined by current guidelines and clinical judgement.

Epidemiology

Menopause is a universal life-course event for women, typically occurring around the late forties to early fifties, and a large proportion of women experience bothersome vasomotor symptoms during the transition, making symptom management a frequent midlife health concern (Pinkerton, 2020).

Evidence & guidelines

The Women's Health Initiative (2002) provided pivotal randomized data on combined estrogen-plus-progestin therapy, prompting a reassessment of its use. Current practice is framed by position statements such as the 2022 hormone therapy position statement of The North American Menopause Society, which supports individualized use for appropriate candidates, and by clinical reviews summarizing the evidence (NAMS, 2022; Pinkerton, 2020).

History

Hormone therapy was widely prescribed in the late twentieth century, partly in the expectation of broad preventive benefits. The Women's Health Initiative results in 2002 substantially changed prescribing by quantifying risks of combined therapy in a randomized design, after which guidance shifted toward individualized, symptom-focused use weighed against personal risk, as reflected in subsequent position statements (Writing Group for the Women's Health Initiative Investigators, 2002; NAMS, 2022).

Debates

How should the benefit-risk balance of hormone therapy be framed?

Following the Women's Health Initiative, debate has centred on the 'timing hypothesis' — that benefits and risks differ by age and time since menopause — and on distinguishing symptom relief in younger, recently menopausal women from longer-term or older use; position statements now favour individualized assessment rather than blanket recommendations.

Seminal works

• whi-2002
• nams-2022

Frequently asked questions

Why did views on menopausal hormone therapy change after 2002?

The Women's Health Initiative randomized trial quantified the risks and benefits of combined estrogen-plus-progestin therapy, which led guidelines to move away from broad preventive use toward individualized, symptom-focused decisions.

Does this entry advise whether to take hormone therapy?

No. It summarizes the biology and evidence as a reference; whether and how hormone therapy is used depends on individual symptoms and risk and is decided with a clinician under current guidelines.